Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis-Reference-Cited by-同舟云学术

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis

Published:2007-11-13 Issue:12 Volume:97 Page:1642-1647
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Debled M,Houédé N,Madranges N,Donamaria C,Floquet A,Durand M,Mauriac Louis

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6604094.pdf

Reference50 articles.

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453

2. Balducci L, Yates J (2000) General guidelines for the management of older patients with cancer. Oncology (Williston Park) 14: 221–227

3. Boleti E, Mead GM (2007) ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 18: 376–380

4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901–906

5. Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686–2693

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy;Life Sciences;2021-07

2. A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity;Cancer Management and Research;2021-05

3. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data;Critical Reviews in Oncology/Hematology;2017-12

4. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring;Cancer Chemotherapy and Pharmacology;2017-06-27

5. Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy;Revista Latino-Americana de Enfermagem;2014-04